← Back to Search

18F-FSPG PET/CT Imaging for Lung Cancer

Phase 2
Led By Carina M Aparici
Research Sponsored by Andrei Iagaru
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be eligible if the dominant nodule is 7 to 30 mm
Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is testing a new imaging agent, 18F-FSPG, to see if it can help diagnose early lung cancer in patients with lung nodules.

Who is the study for?
This trial is for current or former cigarette smokers who have smoked at least the equivalent of a pack a day for 20 years. They must have lung nodules sized between 7 to 30 mm and are already scheduled for standard PET imaging. Pregnant or nursing individuals, those with past lung cancer, or any cancer diagnosis in the last five years cannot participate.Check my eligibility
What is being tested?
The study is testing if using an imaging agent called 18F-FSPG before a PET/CT scan can better diagnose early lung cancer in patients with lung nodules compared to the standard method that uses an agent known as 18F-FDG.See study design
What are the potential side effects?
While not explicitly listed, potential side effects may include reactions to the imaging agents such as mild rash, itching, or discomfort at injection site. The PET/CT procedure itself is generally safe but carries minimal risks associated with radiation exposure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have a lung nodule between 7 to 30 mm, or multiple with one dominant in this size range.
I am scheduled for a PET scan to check a lung nodule.
I have smoked at least 20 pack-years.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) specificity for malignant lung nodules
Secondary outcome measures
Improved performance of prediction model for lung nodules

Side effects data

From 2022 Phase 2 trial • 46 Patients • NCT02448225
Non-cardiac chest pain
Study treatment Arm
Diagnostic (18F-FDG PET/CT, 18F-FSPG PET/CT)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)Experimental Treatment4 Interventions
Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography
Completed Phase 2
Computed Tomography
Completed Phase 2
Fludeoxyglucose F-18
Completed Phase 2
Fluorine F 18 L-glutamate Derivative BAY94-9392
Completed Phase 2

Find a Location

Who is running the clinical trial?

Boston UniversityOTHER
449 Previous Clinical Trials
9,922,143 Total Patients Enrolled
Andrei IagaruLead Sponsor
15 Previous Clinical Trials
546 Total Patients Enrolled
Canary FoundationOTHER
4 Previous Clinical Trials
4,104 Total Patients Enrolled

Media Library

Fluorine F 18 L-glutamate Derivative BAY94-9392 Clinical Trial Eligibility Overview. Trial Name: NCT03824535 — Phase 2
Pulmonary Nodules Research Study Groups: Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)
Pulmonary Nodules Clinical Trial 2023: Fluorine F 18 L-glutamate Derivative BAY94-9392 Highlights & Side Effects. Trial Name: NCT03824535 — Phase 2
Fluorine F 18 L-glutamate Derivative BAY94-9392 2023 Treatment Timeline for Medical Study. Trial Name: NCT03824535 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients currently being recruited for this trial?

"That is correct, the information on clinicaltrials.gov does say that this study is looking for volunteers at the moment. The posting date was February 4th, 2019 and the most recent update was June 16th, 2022. They are searching for 50 individuals total from one location."

Answered by AI

Does BAY94-9392 have FDA approval for treating patients with Fluorine F 18 L-glutamate?

"This chemical, Fluorine F 18 L-glutamate Derivative BAY94-9392, is currently in Phase 2 of clinical trials. This means that while there is evidence suggesting it is safe, none yet affirms that it is an effective medication."

Answered by AI

What medical conditions does Fluorine F 18 L-glutamate Derivative BAY94-9392 help alleviate?

"Fluorine F 18 L-glutamate Derivative BAY94-9392 is often used to ameliorate the effects of CAD. This medication can also improve outcomes for patients with malignancies, positron emission tomography, and left ventricular dysfunction."

Answered by AI

How many individuals are being treated as part of this clinical research?

"That is correct. According to the information found on clinicaltrials.gov, this study was originally posted on February 4th, 2019 and is actively recruiting patients at this time. The goal is to enroll 50 individuals from 1 location."

Answered by AI

What other scientific studies have been done using Fluorine F 18 L-glutamate Derivative BAY94-9392?

"Right now, there are 26 ongoing studies investigating Fluorine F 18 L-glutamate Derivative BAY94-9392. Out of these, 2 are large Phase 3 clinical trials. Most research surrounding this topic is based in New york City; however, one can find 56 different trial locations across the United States."

Answered by AI
~8 spots leftby Feb 2025